Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
0.00%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 823 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Minerva Neurosciences, Inc.
Market Cap
$157.94M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$157.59M
Gross Margin
63.55%
TTM Avg
56.95%
3Y Avg
54.72%
5Y Avg
65.55%
Market Cap
$155.88M
Gross Margin
49.12%
TTM Avg
60.40%
3Y Avg
67.38%
5Y Avg
70.83%
Market Cap
$155.10M
Gross Margin
N/A
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$163.93M
Gross Margin
42.60%
TTM Avg
53.28%
3Y Avg
52.45%
5Y Avg
54.03%
Market Cap
$165.79M
Gross Margin
63.30%
TTM Avg
63.88%
3Y Avg
62.53%
5Y Avg
60.65%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | $157.94M | 0.00% | 0.00% | 0.00% | 0.00% |
| Coherus Oncology, Inc. (CHRS)vs › | $157.59M | 63.55% | 56.95% | 54.72% | 65.55% |
| PepGen Inc. (PEPG)vs › | $158.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| Inogen, Inc. (INGN)vs › | $156.98M | 48.89% | 46.84% | 43.63% | 44.77% |
| Neuronetics, Inc. (STIM)vs › | $155.88M | 49.12% | 60.40% | 67.38% | 70.83% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.10M | N/A | 0.00% | 0.00% | 0.00% |
| LifeMD, Inc. (LFMDP)vs › | $152.55M | 85.91% | 84.21% | 85.09% | 82.87% |
| Quanterix Corporation (QTRX)vs › | $163.93M | 42.60% | 53.28% | 52.45% | 54.03% |
| OptimizeRx Corp. (OPRX)vs › | $165.79M | 63.30% | 63.88% | 62.53% | 60.65% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $149.85M | 0.00% | 0.00% | 0.00% | -29.98% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
